Biohaven Pharmaceutical Holding Company Limited
Biohaven is a Yale spin out company focused on innovative neuroscience compounds for neurodegenerative and neuropsychiatric indications. Its lead drug candidates modulate glutamate with application across a variety of therapeutic indications (orphan neurologic disorders, treatment resistant depression, bipolar depression and anxiety). Biohaven’s two lead compounds (BHV-4157 and BHV-5000) are new chemical entities (NCE) entering the clinic in Phase 3 studies in 2016. Biohaven also has a reformulated (quick-to-market) 505(b)(2) sublingual product developed in conjunction with Catalent Pharma Solutions (BHV-0223 ZYDIS) for development in Lou Gehrig’s disease (ALS).